CPL is focused on the development and commercial manufacturing of non-sterile liquid and semi-solid pharmaceuticals 

PRODUCT DEVELOPMENT: FORMULATION THROUGH VALIDATION

  • ANDA, NDA, 505(b)2 product development expertise
  • New formula development and re-formulation
  • Reverse engineering for generic product formulation
  • In-Vitro Release Testing (IVRT), In-Vitro Permeation Testing (IVPT), and cell-based & cell-free assay testing for skin models
  • Analytical methods development and validation
  • Process scale-up, optimization and qualification
  • Phase I-III clinical trial supplies manufacturing
  • Technology transfer of current products from other sites

COMMERCIAL PRODUCT MANUFACTURING

  • Non-sterile solutions, suspensions, nasal sprays, lotions, gels, creams, ointments
  • Hormone and corticosteroid product capability
  • Flammable and alcohol-based product processing
  • HDPE and glass bottles, airless bottles (including bag-in-bottle), metered dose pumps, multi-dose pumps, cap closures
  • Aluminum and laminate tubes
  • Foil unit dose sachets
  • Product serialization

 PRODUCT TESTING

  • Nasal spray characterization and release
  • Physical and chemical analytical release testing
  • Elemental Impurities Testing
  • In-Vitro Release Testing (GMP)
  • Microbiology testing
  • ICH stability management

 FACILITIES & EQUIPMENT CAPABILITIES

  • US FDA and Health Canada registered manufacturing and testing sites
  • Segregated manufacturing suites with batch sizes between 20kg-5000kg 
  • State-of-the-art twin Symex manufacturing vessels 
  • Versatile filling lines for plastic and glass bottles 
  • 12,000 S.F of modern chemical, micro, skin testing, and stability laboratories
  • Serving US, Canada, Europe, Japanese, Asian Pacific product markets

Contact us

905.821.7600 

Go to article: Home | Two years of Covid-19Go to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: CSafe GlobalGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Controlant Company InsightGo to article: ControlantGo to article: Contract Pharmaceuticals Limited CanadaGo to article: CommentGo to article: Ukraine: Russian invasion could cause spike in Covid-19 cases Go to article: First vaccines, now drugs: FDA’s second wave of emergency Covid-19 approvalsGo to article: International Women’s Day spotlight: endometriosisGo to article: Remote audits – stopgap measure or the new normal?Go to article: Owen Mumford Company Insight Go to article: Owen MumfordGo to article: BaxterGo to article: In DepthGo to article: Two years of Covid-19: lessons the pandemic taught about delivering essential vaccinesGo to article: A perfect storm: Covid-19 viral vector manufacturing adds further burden to CAR-Go to article: Russia sanctions: what next for Sputnik Covid-19 vaccine production around the wGo to article: Profit for patients: can NFTs allow people to monetise their health data?Go to article: Navigating distribution challenges for rare disease drugsGo to article: NiproGo to article: Datwyler Company InsightGo to article: DatwylerGo to article: In DataGo to article: North America is seeing a hiring boom in pharma digital media rolesGo to article: Filings buzz: 23% increase in industrial automation mentions in Q3 of 2021Go to article: Event: Outsourcing in Clinical Trials Europe 2022Go to article: EventsGo to article: Next issue